Potent, selective and reversible ceramide kinase (CerK) inhibitor (IC50 = 12 nM in vitro). Displays selectivity for CerK over sphingosine kinases (IC50 ≥100 μM) and other lipid kinases.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 431.55. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.32 mL||11.59 mL||23.17 mL|
|5 mM||0.46 mL||2.32 mL||4.63 mL|
|10 mM||0.23 mL||1.16 mL||2.32 mL|
|50 mM||0.05 mL||0.23 mL||0.46 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Graf et al (2009) A secondary assay for ceramide kinase inhibitors based on cell growth inhibition by short-chain ceramides. Anal.Biochem. 384 166 PMID: 18831956
Niwa et al (2009) Ceramide kinase deficiency impairs microendothelial cell angiogenesis in vitro. Microvasc.Res. 77 389 PMID: 19323974
If you know of a relevant reference for NVP 231, please let us know.
View Related Products by Product Action
Keywords: NVP 231, supplier, NVP231, potent, reversible, selective, ceramide, kinase, CerK, inhibitors, inhibits, Other, Kinases, Tocris Bioscience
Citations for NVP 231
Citations are publications that use Tocris products.
Currently there are no citations for NVP 231. Do you know of a great paper that uses NVP 231 from Tocris? If so please let us know.